On the 25th of September, Orbimed Capital purchased 1.2 million Prelude Therapeutics Incorporat (PRLD) shares for $23 million at an average price of $19.00 per share.
Shares of Prelude Therapeutics Incorporat are up 57.52% since the transaction.
Orbimed Capital’s holding in Prelude Therapeutics Incorporat established a new holding of about 917 thousand shares with the purchase.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.